dbo:abstract
|
- Protein nanotechnology is a burgeoning field of research that integrates the diverse physicochemical properties of proteins with nanoscale technology. This field assimilated into pharmaceutical research to give rise to a new classification of nanoparticles termed protein (or protein-based) nanoparticles (PNPs). PNPs garnered significant interest due to their favorable pharmacokinetic properties such as high biocompatibility, biodegradability, and low toxicity Together, these characteristics have the potential to overcome the challenges encountered with synthetic NPs drug delivery strategies. These existing challenges including low bioavailability, a slow excretion rate, high toxicity, and a costly manufacturing process, will open the door to considerable therapeutic advancements within oncology, theranostics, and clinical translational research. Continued advancement within this field is required for the clinical translation of PNPs. As of 2022, only one PNP formulation (Abraxane) and five VLPs (Gardasil, Ceravix, Mosquirix, Sci-B-Vac, Gardasil9) are approved by the FDA for clinical use. FDA approval of PNPs formulations is restrained by complications arising from in-vivo interactions between PNPs and the biological environment that jeopardize their safety or function. For example, PNPs may undergo protein conformation changes, form a protein corona, or induce inflammation and may risk patient well-being. (en)
|
dbo:wikiPageID
| |
dbo:wikiPageLength
|
- 35483 (xsd:nonNegativeInteger)
|
dbo:wikiPageRevisionID
| |
dbo:wikiPageWikiLink
| |
dbp:wikiPageUsesTemplate
| |
dcterms:subject
| |
rdfs:comment
|
- Protein nanotechnology is a burgeoning field of research that integrates the diverse physicochemical properties of proteins with nanoscale technology. This field assimilated into pharmaceutical research to give rise to a new classification of nanoparticles termed protein (or protein-based) nanoparticles (PNPs). PNPs garnered significant interest due to their favorable pharmacokinetic properties such as high biocompatibility, biodegradability, and low toxicity Together, these characteristics have the potential to overcome the challenges encountered with synthetic NPs drug delivery strategies. These existing challenges including low bioavailability, a slow excretion rate, high toxicity, and a costly manufacturing process, will open the door to considerable therapeutic advancements within onc (en)
|
rdfs:label
|
- Protein nanoparticles (en)
|
owl:sameAs
| |
prov:wasDerivedFrom
| |
foaf:isPrimaryTopicOf
| |
is dbo:wikiPageRedirects
of | |
is dbo:wikiPageWikiLink
of | |
is foaf:primaryTopic
of | |